64179-41-5

Upstream product

• 64179-40-4 5-nitrospiro<1,3-benzodioxole-2,1'-cyclohexane> 
• 182-55-8 spiro[benzo[d][1,3]dioxole-2,1'-cyclohexane] 
• 120-80-9 benzene-1,2-diol 
• 108-94-1 cyclohexanone 

Downstream Products

• 1228882-53-8 C₂₂H₁₈N₂O₄ 
• 1228882-51-6 2-butyl-6-(3,4-dihydroxyphenylamino)benzo[de]isoquinoline-1,3-dione 
• 921197-36-6 2-phenyl-benzothiazoIe-5,6-diol cyclohexylidene ketal 
• 54826-77-6 3',4'-dihydroxy-N-methylacetanilide 

Relevant academic research and scientific papers

NEW PHARMACEUTICAL COMPOUNDS

Compounds of formula (I), wherein R1-R4, X, Y and Z are as defined in claims, exhibit COMT enzyme inhibiting activity and are thus useful as COMT inhibitors.

Comparative Toxicities and Analgesic Activities of Three Monomethylated Analogues of Acetaminophen

Three monomethylated derivatives of 4'-hydroxyacetanilide (acetaminophen) were prepared in order to compare their cytotoxic potential and analgesic activity with that of acetaminophen.Only 4'-hydroxy-methylacetanilide (N-methylacetaminophen) was devoid of cytotoxic effects to hepatic tissue of mice.Results of comparative tissue distribution studies and metabolism studies both in vivo and in vitro in mice indicate that the disposition of N-methylacetaminophen is similar to that of acetaminophen except that it is not oxidized to a toxic metabolite.In contrast, 3'-methyl-4'-hydroxyacetanilide (3-methlacetaminophen) is as hepatotoxic as acetaminophen in mice while 2'-methyl-4'-hydroxyacetanilide (2-methylacetaminophen) is less hepatotoxic.The analgesic potency of the analogues seems to parallel their hepatotoxic potential, and both activities parallel the oxidation potentials in this series of compounds.